{"id":391720,"date":"2014-03-13T00:00:00","date_gmt":"2014-03-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd0614-biopharma-multiple-sclerosis-relapsing-remitting-decisionbase-us-eu-2014\/"},"modified":"2026-03-31T09:05:42","modified_gmt":"2026-03-31T09:05:42","slug":"dbaspd0614-biopharma-multiple-sclerosis-relapsing-remitting-decisionbase-us-eu-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd0614-biopharma-multiple-sclerosis-relapsing-remitting-decisionbase-us-eu-2014\/","title":{"rendered":"Multiple Sclerosis (Relapsing-Remitting) | DecisionBase | US\/EU | 2014"},"content":{"rendered":"<p><em>How Will the Complex Interplay Between Benefit, Risk, and Cost Impact Prescriber Preferences, and Payer Acceptance of, Future Disease-Modifying Therapies?<\/em><\/p>\n<p>The market for disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis (RR-MS) is highly active and commercially compelling. In spite of a small diagnosed prevalent population relative to many other neurological indications, drug-treatment rates for RR-MS are high, and neurologists emphasize early intervention and long-term treatment to improve long-term outcomes in this chronic disease. The number of disease-modifying therapies approved to treat RR-MS is expanding steadily, including the availability of multiple oral disease-modifying drugs in this historically injectable market. However, because the MS disease course is heterogeneous and therapeutic response is unpredictable, a continued need exists for more-effective, more-tolerable, and less-burdensome treatment alternatives.<\/p>\n","protected":false},"template":"","class_list":["post-391720","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391720","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391720\/revisions"}],"predecessor-version":[{"id":394843,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391720\/revisions\/394843"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391720"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}